Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 21

The DOI matches its Crossref record.

Causality assessment: Which is best-expert opinion or RUCAM?

Lewis, James H.·2014·Clinical Liver Disease

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cld.365

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 38

  1. Zimmerman HJ Hepatotoxicity. The adverse effect of drugs and other chemicals on the liver 2nd edition Philadelphia, PA Lippincott Williams & Wilkins 1999
  2. Temple, 2006, Hy's Law: Predicting serious hepatotoxicity, Pharmacoepidemiol Drug Saf, 15, 241, 10.1002/pds.1211 · DOI · Paper page
  3. Lewis, 2013, Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed, Perspectives of a clinical hepatologist. Pharmaceutical Med, 27, 165
  4. Standardization of definitions and criteria of causality assessment of adverse drug reactions, 1990, Drug-induced liver disorders: report of an international consensus meeting, Int J Clin Pharmacol Ther Toxicol, 28, 317
  5. Danan, 1993, Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  6. Benichou, 1993, Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge, J Clin Epidemiol, 46, 1331, 10.1016/0895-4356(93)90102-7 · DOI · Paper page
  7. Shapiro, 2007, Causality assessment of drug-induced hepatotoxicity: promises and pitfalls, Clinical Liver Disease, 11, 477, 10.1016/j.cld.2007.06.003 · DOI
  8. Garcia-Cortes, 2008, Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury, Aliment Pharmacol Ther, 27, 780, 10.1111/j.1365-2036.2008.03655.x · DOI · Paper page
  9. Teschke, 2013, Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods, World J Gastroenterol, 19, 2864, 10.3748/wjg.v19.i19.2864 · DOI · Paper page
  10. Garcia-Cortes, 2011, Causality assessment methods in drug induced liver injury: strengths and weaknesses, J Hepatol, 55, 683, 10.1016/j.jhep.2011.02.007 · DOI · Paper page
  11. Corsini, 2012, Current challenges and controversies in drug-induced liver injury, Drug Saf, 35, 1099, 10.1007/BF03261997 · DOI
  12. Lucena, 2008, Assessment of drug-induced liver injury in clinical practice, Fundam Clin Pharmacol, 22, 141, 10.1111/j.1472-8206.2008.00566.x · DOI
  13. Kaplowitz, 2001, Causality assessment versus guilt-by-association in drug hepatotoxicity, Hepatology, 33, 308, 10.1053/jhep.2001.21083 · DOI
  14. Hawkins, 2012, Latest advances in predicting DILI in human subjects: focus on biomarkers, Expert Opin Drug Metab Toxicol, 8, 1521, 10.1517/17425255.2012.724060 · DOI
  15. Schomaker, 2013, Assessment of emerging biomarkers of liver injury in human subjects, Toxicol Sci, 132, 276, 10.1093/toxsci/kft009 · DOI
  16. Antoine, 2013, Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital, Hepatology, 58, 777, 10.1002/hep.26294 · DOI · Paper page
  17. Lucena, 2001, Comparison of two clinical scales for causality assessment in hepatotoxicity, Hepatology, 33, 123, 10.1053/jhep.2001.20645 · DOI · Paper page
  18. Sgro, 2002, Incidence of drug-induced injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
  19. Lewis, 2008, Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran, Int J Clin Pharmacol Ther, 46, 327, 10.5414/CPP46327 · doi:10.5414/cpp46327
  20. Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel Uclaf Causality Assessment Method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
  21. Graham, 2003, Troglitazone-induced liver failure: a case study, Am J Med, 114, 299, 10.1016/S0002-9343(02)01529-2 · DOI · Paper page
  22. Fontana, 1999, Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group, Liver Transpl Surg, 5, 480, 10.1002/lt.500050607 · DOI
  23. Brinker, 2009, Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases, Hepatology, 49, 250, 10.1002/hep.22620 · DOI
  24. Robles-Diaz, 2014, Use of Hy's Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury, Gastroenterology, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  25. Lewis, 2012, MacSween's Pathology of the liver, 645, 10.1016/B978-0-7020-3398-8.00013-1 · DOI
  26. Kleiner, 2014, Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations, Hepatology, 59, 661, 10.1002/hep.26709 · DOI · Paper page
  27. Gupta, 2008, Review article: the use of potentially hepatotoxic drugs in patients with liver disease, Aliment Pharmacol Ther, 28, 1021, 10.1111/j.1365-2036.2008.03822.x · DOI
  28. Lewis, 2013, Review article: prescribing medications in patients with cirrhosis-a practical guide, Aliment Pharmacol Ther, 37, 1132, 10.1111/apt.12324 · DOI · Paper page
  29. Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI
  30. Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
  31. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
  32. Bell, 2012, Serum proteomic profiling in patients with drug-induced liver injury, Aliment Pharmacol Ther, 35, 600, 10.1111/j.1365-2036.2011.04982.x · DOI
  33. Steuerwald, 2013, Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance, PLoS One, 8, e81974, 10.1371/journal.pone.0081974 · DOI
  34. Daly, 2013, Pharmacogenomics of adverse drug reactions, Genome Med, 5, 5, 10.1186/gm409 · DOI
  35. Hoofnagle, 2013, LiverTox: a website on drug-induced liver injury, Hepatology, 57, 873, 10.1002/hep.26175 · DOI · Paper page
  36. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
  37. Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 · DOI · Paper page
  38. Watkins, 2013, Managing the risk of drug-induced liver injury, Clin Pharmacol Ther, 94, 629, 10.1038/clpt.2013.182 · DOI

Cited by

See all 21

Metadata

Authors
Lewis, J. H.
Affiliations
Division of Gastroenterology and Hepatology; Georgetown University Hospital; Washington DC
Venue
Clinical Liver Disease
Published
2014-07
Volume
4
Issue
1
Pages
4-8
ISSN
2046-2484
Cited by
21
References
0
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 427 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Causality assessment: Which is best-expert opinion or RUCAM? https://app.cochat.ai/papers/10.1002/cld.365
The paper
Lewis, J. H. (2014). Causality assessment: Which is best-expert opinion or RUCAM? Clinical Liver Disease. https://doi.org/10.1002/cld.365

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.